Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7215186

["Hyperthyroiditis" (author's transl)].

D Luft·M Eggstein
View original source ↗Export metadata ↓

Abstract

Typical signs of so-called hyperthyroiditis are hyperthyroidism, low iodine uptake by the thyroid, absence of local, general or humoral signs of inflammation, and absence of significant antibody titres against thyroid tissue. These features are illustrated by the case report of a 51-year-old man. Since the course of hyperthyroidism is short and has a good prognosis, the importance of the diagnosis lies in avoiding unnecessary therapeutic measures. This cause of hyperthyroidism can be recognized only by including tests of intrathyroid iodine metabolism among diagnostic procedures.

Explore related subjects

AntibodiesHumansHyperthyroidismMaleMiddle AgedPrognosisThyroid GlandThyroiditisCase ReportsEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Luft, M Eggstein. 1981-05-01. ["Hyperthyroiditis" (author's transl)].. https://doi.org/10.1055/s-2008-1070358

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2021

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies↗